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Abstract In clinical practice natalizumab is typically
used in patients who have experienced breakthrough dis-
ease during treatment with interferon beta (IFNb) or gla-
tiramer acetate. In these patients it is important to reduce
disease activity as quickly as possible. In a phase II study,
differences between natalizumab and placebo in MRI
outcomes reflecting inflammatory activity were evident
after the first infusion and maintained through a 6-month
period, suggesting a rapid onset of natalizumab treatment
effects. To explore how soon after natalizumab initiation
clinical effects become apparent, annualized relapse rates
per 3-month period and time to first relapse were analyzed
in the phase III AFFIRM study (natalizumab vs. placebo)
and in the multinational Tysabri Observational Program
(TOP). In AFFIRM, natalizumab reduced the annualized
relapse rate within 3 months of treatment initiation com-
pared with placebo in the overall population (0.30 vs. 0.71;
p \ 0.0001) and in patients with highly active disease
(0.30 vs. 0.94; p = 0.0039). The low annualized relapse
rate was maintained throughout the 2-year study period,
and the risk of relapse in AFFIRM patients treated with
natalizumab was reduced [hazard ratio against placebo 0.42
(95 % CI 0.34–0.52); p \ 0.0001]. Rapid reductions in
annualized relapse rate also occurred in TOP (baseline 1.99
vs. 0–3 months 0.26; p \ 0.0001). Natalizumab resulted in
rapid, sustained reductions in disease activity in both
AFFIRM and in clinical practice. This decrease in disease
activity occurred within the first 3 months of treatment
even in patients with more active disease.
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Introduction
For patients with multiple sclerosis (MS), rapid control of
disease activity is an important goal of therapy [1]. When
clinical exacerbations are frequent and/or levels of radio-
logically apparent disease activity are high, effective
treatment is especially crucial because the inflammation
associated with active disease may lead not only to
demyelination but also to potentially irreversible neuronal
damage [2–6]. Disease-modifying therapies (DMTs) for
the treatment of MS have been shown to reduce relapse
rates and disability progression in pivotal studies over
L. Kappos (&)
Departments of Neurology and Biomedicine,
University Hospital Basel, Petersgraben 4, Basel, Switzerland
e-mail: lkappos@uhbs.ch
P. W. O’Connor
MS Clinic, St. Michael’s Hospital, 3 Suther Wing D. Room
3007, 30 Bond Street, Toronto, ON, Canada
C. H. Polman
VU Medical Centre, PO Box 7057, 1007 MB Amsterdam,
The Netherlands
P. Vermersch
Department of Neurology, Clinique neurologique, Hoˆpital Roger
Salengro, University of Lille Nord de France, CHU de Lille,
Rue Emile Laine, 59037 Lille Cedex, France
H. Wiendl
Department of Neurology-Inflammatory Diseases of the Nervous
System and Neurooncology, Neurology Clinic, University
of Mu¨nster, Domagkstrasse 13, Munster, Germany
A. Pace  A. Zhang  C. Hotermans
Biogen Idec Inc., 133 Boston Post Road,
Weston, MA 02493, USA
123
J Neurol (2013) 260:1388–1395
DOI 10.1007/s00415-012-6809-7
1–2 years [7–11]. Clinical effects occurring earlier than
1 year after initiation of therapy have not yet been well
studied. Some studies, however, have shown significant
benefits on annualized relapse rates and/or the number of
gadolinium-enhancing lesions with DMTs versus placebo
at 6 months, suggesting that the clinical effects of therapy
could be detectable at earlier time points as well [12–14].
Natalizumab (Tysabri, Biogen Idec, Weston, MA, and
Elan Pharmaceuticals, Inc., San Francisco, CA) is a
recombinant humanized monoclonal antibody that inhibits
binding of the a4 subunit of the a4b1 and a4b7 integrins to
their endothelial receptors and prevents trafficking of
mononuclear leukocytes across the vascular endothelium
of the central nervous system (CNS) [15, 16]. In its pivotal
monotherapy trial (AFFIRM), natalizumab showed efficacy
at 1 and 2 years in treatment-naı¨ve patients with relapsing
forms of MS [15]. Analysis of 2-year data from AFFIRM
revealed that natalizumab was also effective in the sub-
group of patients with highly active disease, defined as
having C2 relapses in the year before study entry and C1
gadolinium-enhancing lesion at study entry [17]. In addi-
tional studies, natalizumab was effective as a second-line
therapy in patients with insufficient response to other
DMTs [18–22].
Results from the phase II study suggest that natalizumab
may reduce disease activity shortly after treatment initiation.
At 1 month, the mean number of new gadolinium-enhancing
lesions had already diverged between natalizumab- and
placebo-treated patients, and the difference was maintained
over time. At 6 months, there was an overall 89-93 %
reduction of new gadolinium-enhancing lesions with natal-
izumab compared with placebo, as well as a significant
reduction in the number of relapses [14].
To further explore when the effects of natalizumab on
clinical relapses occur and whether the time course of
clinical effects is dependent on the degree of baseline
disease activity, we conducted post hoc analyses of data
from AFFIRM. Because clinical practice likely has greater
variability in patient characteristics compared with clinical
trials, data from the clinical practice-based TYSABRI
Observational Program (TOP) were also analyzed [23].
Materials and methods
Study design—AFFIRM
AFFIRM was a randomized, double-blind, placebo-
controlled, phase III clinical study, in which 942
patients received natalizumab 300 mg or placebo (2:1)
by intravenous (i.v.) infusion once every 4 weeks for up
to 116 weeks [15]. Relapses were defined as new or
recurrent neurologic symptoms not associated with
fever or infection that lasted C24 h and were accom-
panied by new neurologic signs found by the examining
neurologist. Post hoc subgroup analyses of data from
AFFIRM defined highly active disease as C2 relapses
in the year before study entry and C1 gadolinium-
enhancing lesion on T1-weighted magnetic resonance
imaging (MRI) at study entry [17].
Study design—TOP
Tysabri Observational Program is an ongoing 10-year,
open-label, multinational, multicenter, prospective obser-
vational study evaluating the long-term safety and efficacy
of natalizumab in the postmarketing clinical practice set-
ting. As of December 1, 2011, 3,976 patients were enrolled
[24].
In TOP, a clinical relapse is defined as new or recurrent
neurological symptoms, not associated with fever, lasting
for at least 24 h, and followed by a period of 30 days of
stability or improvement. New or recurrent neurological
symptoms that occur less than 30 days following the onset
of a protocol-defined relapse should be considered part of
the same relapse.
Table 1 Baseline annualized relapse rates for patients in AFFIRM and TOP
AFFIRM TOP
Natalizumab Placebo Natalizumab
Overall HA Overall HA Overall
Patients, n 627 148 315 61 3,963a
Relapses during prior year, n
Mean ± SD 1.53 ± 0.91 2.45 ± 1.19 1.50 ± 0.77 2.28 ± 0.55 1.99 ± 1.03
95 % CI 1.46–1.60 2.25–2.64 1.42–1.59 2.14–2.42 1.96–2.03
Median (range) 1 (0–12) 2 (2–12) 1 (0–5) 2 (2–4) 2 (0–10)
HA highly active, defined as having C2 relapses in the year before study entry and C1 gadolinium-enhancing lesion at study entry
a Baseline relapse rates were not available for 13 patients in TOP
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AFFIRM and TOP were approved by the appropriate
ethics committees and performed in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines. All patients provided written informed consent.
Statistical analysis
Analyses were conducted for overall AFFIRM and TOP
populations and for the subgroup of AFFIRM patients with
highly active disease. Annualized relapse rates per 3-month
interval were calculated as the total number of relapses
divided by total person-years observed within the interval.
Point estimates, confidence intervals (CIs), and treatment
effects (rate ratios) for each interval were estimated from a
Poisson model with overdispersion. For TOP data, annu-
alized relapse rates were estimated at each time point using
a negative binomial model. Treatment effects on time to
first relapse (in days) at a specific time point were assessed
using hazard ratios (HR) estimated from a Cox propor-
tional hazards model, adjusting for the number of relapses
in the year before study entry. The cumulative probability
of relapse was estimated using the Kaplan–Meier method,
and 95 % confidence bands were derived using the equal
precision approach [25]. A log-rank test was used to
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Fig. 1 Annualized relapse rate over time (calculated for each
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determine the first day a significant difference in the
cumulative probability of relapse emerged between study
groups.
Results
Baseline relapse rates
Relapse rates at baseline for patients in AFFIRM and TOP
are shown in Table 1. Overall, the mean baseline relapse
rate in AFFIRM was 1.5 relapses in the prior year. A total
of 209 patients (148 natalizumab and 61 placebo) in
AFFIRM met the criteria for highly active MS, with a
mean relapse rate of 2.5 relapses in the year prior to study
entry.
The median (range) disease duration prior to starting
natalizumab was similar for the two studies: 5 (0–34) years
for AFFIRM and 7 (0–44) years for TOP [15, 23]. The
majority (90 %) of TOP patients had used another DMT
prior to starting natalizumab [23]. The mean relapse rate at
baseline among TOP patients was approximately 2.0,
similar to the rate in AFFIRM patients with highly active
disease (Table 1).
Annualized relapse rate
In AFFIRM natalizumab monotherapy reduced annualized
relapse rate already within the first 3 months of treatment
compared with placebo overall [0.30 (95 % CI 0.23–0.40)
vs. 0.71 (95 % CI 0.55–0.91); p \ 0.0001] and in patients
with highly active disease [0.30 (95 % CI 0.17–0.53) vs.
0.94 (95 % CI 0.55–1.63); p = 0.0039]. This treatment
effect was maintained throughout the 2-year controlled
study period and was observed despite the fact that sizeable
reductions from baseline annualized relapse rate occurred
also in the placebo group (Fig. 1).
In TOP, annualized relapse rate was reduced from 1.99
(95 % CI 1.96–2.03) at baseline to 0.26 (95 % CI
0.23–0.30; p \ 0.0001) after 3 months of natalizumab
treatment and was maintained at that rate at 4 years
(Fig. 2).
Time to first relapse
Kaplan–Meier curves estimating the cumulative probabil-
ity of relapse over 2 years in AFFIRM patients overall and
in those with highly active disease are shown in Fig. 3. A
significant treatment effect comparing natalizumab versus
placebo was observed at 8 weeks after initiating treatment
(Table 2). A difference in the cumulative probability of
relapse from baseline between the two groups was first
observed at day 42 in patients overall, 5.4 % for natal-
izumab and 9.3 % for placebo (HR: 0.56, 95 % CI
0.34–0.93; p = 0.0238), and at day 45 in patients with
highly active disease, 6.8 % for natalizumab and 16.6 %
for placebo (HR: 0.35, 95 % CI 0.14–0.87; p = 0.0243).
The treatment effect was maintained at 2 years. Overall,
natalizumab treatment reduced the risk of relapse by 58 %
over 2 years relative to placebo (p \ 0.0001). In patients
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Fig. 2 Annualized relapse rate over time in TOP patients is shown as a solid line; 95 % CIs are indicated by dashed lines. Five patients did not
receive natalizumab and were excluded from post-baseline analyses
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with highly active disease, natalizumab reduced the risk
of relapse by 75 % over 2 years relative to placebo
(p \ 0.0001).
At 4, 8, and 12 weeks in TOP, patients treated with
natalizumab had an estimated 2.4, 4.0, and 5.7 % cumu-
lative risk of relapse from baseline, respectively. At
2 years, the estimated risk was 32 %, similar to the risk in
natalizumab-treated AFFIRM patients at 2 years. At
3 years in TOP, the cumulative risk of relapse was 42 %
(Fig. 4).
Discussion
In AFFIRM, natalizumab had a significant effect on
annualized relapse rate within 3 months of initiating ther-
apy, and reductions were sustained over the 2-year con-
trolled study period. Combined with the MRI findings of
the phase II study in which reductions in the mean number
of new gadolinium-enhancing lesions in natalizumab-trea-
ted patients versus placebo were apparent after 1 month
and remained reduced as long as treatment was continued
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[14], these data suggest that natalizumab reduces disease
activity shortly after initiating treatment.
Natalizumab also had a significant effect on the cumu-
lative probability of relapse over 2 years, with significant
reductions being observed by 8 weeks after starting treat-
ment. These rapid, sustained reductions in annualized
relapse rate and risk of relapse with natalizumab treatment
occurred regardless of baseline disease activity in the
overall population and in the subset of patients with highly
active disease.
Observations from a clinical practice setting (TOP) were
similar to the clinical trial results but should be interpreted
with caution owing to the lack of a reference group.
Nevertheless, given the differences in patient demograph-
ics and disease characteristics between the clinical studies
and TOP, these results suggest that the results from the
Table 2 Cumulative risk of
relapse from baseline for
patients in AFFIRM
HA highly active, defined as
having C2 relapses in the year
before study entry and C1
gadolinium-enhancing lesion at
study entry
Overall HA
Natalizumab Placebo Natalizumab Placebo
Cumulative risk of relapse at 4 weeks from baseline
Percentage 4.6 4.8 6.1 8.3
HR (95 % CI) 0.96 (0.51–1.79) 0.72 (0.24–2.16)
p value 0.8893 0.5578
Cumulative risk of relapse at 8 weeks from baseline
Percentage 5.7 12.2 6.8 16.6
HR (95 % CI) 0.45 (0.29–0.72) 0.35 (0.14–0.87)
p value 0.0007 0.0243
Cumulative risk of relapse at 12 weeks from baseline
Percentage 7.2 16.7 7.4 20.0
HR (95 % CI) 0.41 (0.28–0.61) 0.33 (0.14–0.76)
p value \0.0001 0.0090
Cumulative risk of relapse at 24 weeks from baseline
Percentage 11.9 25.4 14.2 33.3
HR (95 % CI) 0.43 (0.31–0.59) 0.37 (0.20–0.68)
p value \0.0001 0.0015
Cumulative risk of relapse at 48 weeks from baseline
Percentage 20.0 39.2 21.7 58.9
HR (95 % CI) 0.45 (0.35–0.57) 0.28 (0.17–0.45)
p value \0.0001 \0.0001
Cumulative risk of relapse at 104 weeks from baseline
Percentage 28.7 55.7 29.3 76.0
HR (95 % CI) 0.42 (0.34–0.52) 0.25 (0.17–0.39)
p value \0.0001 \0.0001
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pivotal studies are applicable to those patients included in
the current label of natalizumab. This is particularly
remarkable regarding the potential utility of natalizumab
for patients experiencing MS disease activity despite
treatment with other DMTs to rapidly gain control of dis-
ease and help prevent further cumulative damage.
Our findings are consistent with those of numerous
post-marketing studies that have observed significant
improvements in annualized relapse rate, radiologic disease,
ambulation, or disability progression in patients, including
those with highly active disease, switching to natalizumab
from other DMTs, although most assessments were performed
at 1 year after initiating natalizumab [18, 19, 21, 22, 26–32].
The results of this analysis are also consistent with a separate
AFFIRM analysis that showed an increased probability of
sustained improvement in Extended Disability Status Scale
(EDSS) scores with natalizumab compared with placebo
emerging during the first 24 weeks of treatment [33].
Natalizumab’s rapid effects and ability to control dis-
ease in patients with highly active MS may be best
explained by the inhibition of leukocyte migration into
brain tissue that prevents lesion formation and reduces
inflammatory cell recruitment into existing lesions [34, 35].
In addition to preventing leukocyte entry into the CNS,
there is evidence that natalizumab may dampen ongoing
inflammation in the CNS by disrupting interactions
between inflammatory leukocytes and extracellular matrix
proteins such as fibronectin and osteopontin or by inducing
apoptosis of activated T cells [36–38].
In summary, rapid onset of natalizumab clinical efficacy
shortly after treatment initiation may provide both short-
and long-term benefits.
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